Results 201 to 210 of about 1,703,142 (259)

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Diagnostic Ambiguity in BCR-ABL1-Positive MPAL in a Resource-Limited Setting: A Case Report. [PDF]

Case Rep Hematol
Poudel S, Sharma S, Kafle S, Karki S, Shrestha A.   +4 more
europepmc   +1 more source

Advancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translation

MedComm, Volume 7, Issue 10, October 2026.
In vivo CAR‐T cell generation directly engineers endogenous T cells using pre‐manufactured gene delivery vectors that target T cells and deliver CAR‐encoding genetic material. The resulting CAR‐T cells expand in vivo and mediate antigen‐specific cytotoxicity.
Zhenxin Bai, Ming Yi, Shengtao Hu, Dixuan Xue, Luxin Wei, Lifeng Zhang, Zhijun Dai   +6 more
wiley   +1 more source

Treatment of Leukemia Cutis Secondary to T‐Cell Prolymphocytic Leukemia With Upadacitinib

eJHaem, Volume 7, Issue 5, October 2026.
Kaela Fraser, Courtney Langille, Luke Y. C. Chen, Kerri Purdy   +3 more
wiley   +1 more source

Immune‐Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy

MedComm, Volume 7, Issue 10, October 2026.
Immune‐cell dynamics in the tumor microenvironment converge on four major barriers to effective therapy: failed immune access, defective antigen visibility and priming, loss of effector maintenance, and suppressive tissue remodeling. These barriers emerge from local hypoxic, cytokine, metabolic, and stromal signals.
Pin Guo, Yizhao Xie, Rui Song, Mengdi Yang, Zhen Lin, Chao Guan, Zechen Wang, Jin Wen, Guang‐Liang Chen   +8 more
wiley   +1 more source

Pneumomediastinum and Subcutaneous Emphysema After Rapid Mediastinal Mass Regression

eJHaem, Volume 7, Issue 5, October 2026.
Fahad Alsayed, Ailish Coblentz, Oussama Abla   +2 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Acute myeloid leukemia with unusual mature lymphoid-like morphology in a subset of blasts. [PDF]

J Hematop
Vossen C, E Jordan C.
europepmc   +1 more source

Cross‐Talk Between Histamine H2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT This study investigates the impact of histamine H2 receptor activation on glucocorticoid receptor (GR)‐mediated transcriptional activity, as well as its effects on leukemic cell proliferation and chemotherapy resistance. We demonstrate that activation of the histamine H2 receptor by its specific agonist, amthamine, enhances GR transcriptional ...
Valeria Torralba‐Agu, Natalia Fernández, Carina Shayo, Carlos Davio, C. Daniel Zappia, Federico Monczor   +5 more
wiley   +1 more source

Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3‐Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia

Phytotherapy Research, Volume 40, Issue 10, Page 5988-6004, October 2026.
Overview of the antileukemic effects of Piper nigrum extract in AML. P. nigrum reduced leukemic cell proliferation and glycolytic metabolism through modulation of the PI3K/AKT/mTOR pathway. In vivo, treatment reduced leukemic burden, improved hematological parameters, prolonged survival, and modulated antitumor immune responses.
Natalia Murillo, Paola Lasso, Claudia Urueña, Susana Fiorentino   +3 more
wiley   +1 more source